Open Orphan Share Discussion Threads

[trader_3] 01/12/2020 10:24

Dr Chiu - Ethical Approval for Covid CHIMs

‘Ethical approval is a multi-stage process, and we are just about to get approval to start the screening,” said Dr Chiu. ‘I hope that we will be able to start recruiting (volunteers) around late November.’R30;.

… Dr Chiu. ‘We hope to present our findings to the ethics committee around the time we start screening, and we will be publishing the protocol and the public engagement findings as well.”

hxxps://www.sciencemuseumgroup.org.uk/blog/coronavirus-should-we-infect-young-people-with-covid-19/?utm_source=Twitter&utm_medium=Organic%20Link&utm_campaign=L%20AP:%20Science%20Museum%20Group%20Blog%2018/11/20

Based on the above, Dr Chiu should have presented his evidence to the Ethics Committee by now, so presumably we are due a regulatory decision from this week onwards?

[rafboy] 01/12/2020 09:53

Nice to hear. Yes looks nicely set up here so will be adding when I can. Must catch up properly sometime.

[rafboy] 01/12/2020 09:39

Hi M5 keeping well here and trust you are good too. Watching AGL but FDA is some months away yet.

[m5] 01/12/2020 09:36

Good to see you here!! I hope you are well. You still in AGL? Watching that one carefully as due a reversal, just keeping an eye on the chart for a signal. Good luck.

[rafboy] 01/12/2020 09:12

Taken a position here over the last week or so. Must admit it does look likely to breakout soon.

[molatovkid] 01/12/2020 09:07

Agreed....watch the presentations, see where Orphan are going and you just know.

Just a question of when now and a killer RNS to light the touchpaper.

[sh0wmethemoney] 01/12/2020 08:55

We had the same at 16p and then went on to double.

[sh0wmethemoney] 01/12/2020 08:52

I am with u there m5,like a coiled spring ready to pop IMO.

[m5] 01/12/2020 08:49

Call its ramping if you like, but my bones are telling me that when this pops its going to pop in a big way. I have seen these consolidation patterns many times before and I would say that when a share is in a firm uptrend, as we have here, the tighter the consolidation the bigger the move. Lets see what happens. I am going to stick my neck out and say we will see 40p minimum by Xmas.

DYOR, NOT ADVICE, MY PERSONAL OPINION.

[sh0wmethemoney] 01/12/2020 08:32

Tick up from the 24.5 - 25.5p soon by the look of it.

[warranty] 30/11/2020 20:31

Good find Trader, I think it’s pretty clear now that the regulators are going to certify the COVID CHIMs but it’s just a question of when. Hopefully it will be soon because I feel that might be the catalyst that sets the Orph share price on the next leg up.

[trader_3] 30/11/2020 19:07

Exploring Risks of Human Challenge Trials for COVID-19

‘In this paper, the researchers present an interactive model for exploring some of the risks of a SARS-COV-2 dosing study, which is a prerequisite for COVID-19 human challenge trials….

….since this infection fatality rate will be further reduced in an actual HCT through screening for comorbidities and providing aggressive treatment for any cases that do occur, the team projects the actual risk to be only around 3.1 per 100,000, with a 99.85% probability of no fatalities and a 98.7% chance of no one getting hospitalized….

…According to the authors, it is likely that HCTs are a viable method of rapidly testing vaccine efficacy, which is even more critical during a raging pandemic.’
“It seems likely that Challenge trials are a viable way to rapidly test vaccine efficacy, which is particularly critical now for testing second-generation vaccines, which may prove superior to first generation vaccines, or at least help fill the demand unmet by first-generation candidates.”

hxxps://www.news-medical.net/news/20201130/What-are-the-risks-associated-with-human-challenge-trials-for-SARS-CoV-2-vaccine-candidates.aspx

hxxps://www.medrxiv.org/content/10.1101/2020.11.19.20234658v1.full.pdf

Similar to the recent liability insurance cover (announced by the UK Gov business secretary), this is another important prerequisite positive ‘tick in the box’, for the Covid CHIM implementation.

[m5] 30/11/2020 14:35

Afternoon all. Interesting reversal potentially coming into play. As always intra noise until its confirmed at the close, but there has definitely been a pattern. For the past 5 weeks we have seen the same, its plain to see when looking at the weekly chart, where one candle gives you the weeks trading overview. Huge support area.

20 Minutes to go, down a penny to evens. News anybody?

[trader_3] 30/11/2020 11:07

UK Gov - Medicines and Diagnostic Manufacturing Transformation Fund

Prime Minister Boris Johnson said:

“This new £20m fund will significantly increase the capacity and resilience of our medicines and diagnostics manufacturing supply chains and equip us to fight future health crises.

Throughout the pandemic we have seen a coming together of British scientific industry and innovation and this new fund will enhance the UK’s manufacturing capabilities even further.”

Business Secretary Alok Sharma said:

“The positive and timely response of our medicines manufacturers to the pandemic has been remarkable, but we want to ensure that the UK’s supply chains are even more resilient in the future.

“There are huge opportunities for innovation in medicines and diagnostics, and this new fund will put the UK head and shoulders above others, boosting the UK’s capabilities and generating significant economic opportunities across the country.”

The pandemic has shown the importance of having a strong domestic medicines and diagnostics manufacturing industry. This new fund has been established to grow and strengthen the UK’s capabilities, by encouraging companies to develop new technologies, build new factories and harness new advances, including bioprocessing, data and using greener manufacturing processes.”



Not specifically related to vaccine testing but signals a great future for UK companies like ORPH.

[uapatel] 30/11/2020 10:21

Well if one assumes our CEOs view on a decade long shift to use of our labs etc. Then that’s a lot of new data each year going forward.

So hopefully a recurring revenue deal.

[pogue] 30/11/2020 10:18

I assume we sell access to the database, which is being constantly updated as more data is gathered, wearables manufacturer writes the algorithm that works out what the wearer's health problem is based on the data. As to how we are selling I have no idea exclusive or be a provider to the market, depends on what method gives the best profit or what buyers will pay for, only person that knows that is CF I suggest.

[malcolmmm] 30/11/2020 10:00

I would have thought that the wearables use the data bases, ORPH etc, to test for certain conditions on the wearer to trigger an alert. I dont really know ,interesting though

[molatovkid] 30/11/2020 09:44

On the hvivo wearables data side of things....would any deal with a phone provider be exclusive or non-exclusive ??

I'd like to think non-exclusive obviously...

[trader_3] 30/11/2020 09:34

EU Tender - Future Infectious Disease Threats to Europe: A Foresight Approach


Cathal has previously described the future of ORPH linked to “entering a decade of exponential vaccine development".

If any further proof was needed, below is a European Union tender for Future Infectious Disease Threats to Europe, stating:

‘The goal of this tender is to: ‘Identify the threat spectrum from emerging infectious diseases (EID) in Europe over the next 3 to 8 years’…..

….and drive vaccine development that can be used for infectious disease control and countermeasures.’



As ORPH is the world’s leading company in vaccine and anti viral testing, the short to long term future, looks extremely secure.

IMHO

[666james] 29/11/2020 19:52

Trader_3 very good video as you say Dr Catchpole comes across very professional.

Thanks

[1gw] 29/11/2020 17:07

What chance an RNS before long on a Chinese contract? At the proactive webinar (19th Nov), if I heard it right, CF talked about being happy to help the Chinese government to develop a challenge study and commented on "huge opportunities there to get very near term cash."

That sounded to me like if it comes off it might come off before an Imutex deal, so if I had to rank opportunities in calendar order it might be:

o Chinese challenge study development;
o Terms agreed for access to third quarantine facility;
o Data deal for wearables;
o Imutex sale/reverse.

Of course any, all or none of those might actually happen, but it's an exciting list of relatively near-term possibilities. A deal for quarantine facility access might come with news of contracts to use that facility (perhaps with non-refundable deposits if they are for Covid challenge studies).

[trader_3] 29/11/2020 16:10

CBC News Network speaks to Dr Andrew Catchpole, chief scientific officer at hVIVO


hxxps://www.cbc.ca/player/play/1825106499716

Dr Catchpole adding to the ongoing debate in Canada over Covid CHIM’s – always comes across very well when interviewed.

[trader_3] 29/11/2020 13:38

hVIVO consortium partner Leiden University publishes Covid CHIM Risk Assessment Paper

Conclusion

In this report, we show that risks associated with the experimental infection of human volunteers with SARS-CoV-2 can be minimized if proper mitigation strategies are put in place, leaving a residual risk that should be weighed carefully against the scientific and social values of such a human SARSCoV-2 model.

hxxps://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1784/6009505?searchresult=1

hxxps://hvivo.com/aboutus/clinical-trial-consortium/

Good to see our partners at Leiden Universtity, progressing the Covid CHIM discussion in the Netherlands.

I would anticipate an ORPH RNS at some point, once the discussions have been completed and they are nearer to implementation.

IMHO